A phase I/II, open-label study evaluating twice-daily administration of momelotinib (GS-0387, CYT387) in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis

Authors
Category Primary study
JournalHaematologica
Year 2014
This article has no abstract
Epistemonikos ID: 14a925201489d11cd43494a0e74872df9a5afca7
First added on: Feb 06, 2025